血液肿瘤精准诊治

张曦

doi:10.16016/j.2097-0927.202310109

您当前的位置：

首页 >

文章列表页 >

血液肿瘤精准诊治

专题报道：血液肿瘤诊治前沿 | 更新时间：2026-01-09

- 血液肿瘤精准诊治
- Precision diagnosis and treatment for hematological malignancies
- 陆军军医大学学报 2024年46卷第4期页码：299-310
- 作者机构：
  
  1.400037 重庆，陆军军医大学(第三军医大学)第二附属医院血液病医学中心，全军临床重点专科，创伤与化学中毒全国重点实验室，重庆市临床重点专科，血液病与微环境重庆市重点实验室
  2.401329 重庆，金凤实验室
- 作者简介：
  
  [张曦，博士，主任医师、教授，博士(后)导师，长江学者特聘教授。担任中华医学会血液学分会常务委员、造血干细胞应用学组副组长，中国医师协会血液科医师分会常务委员，中国病理生理学会实验血液学专委会常务委员，中国抗癌协会血液肿瘤专委会常务委员，重庆市医学会血液病专委会主任委员(第五、六届)，重庆市中西医结合学会常务理事等学术任职。主持国家干细胞重点研发专项、国家自然科学基金重点项目、军队课题重点项目、重庆市自然科学基金重点课题等46项；获国家科技进步二等奖1项，中华医学科技奖一等奖1项，重庆市科技进步一等奖2项、二等奖1项，军队医疗/科技成果二等奖3项，中国抗癌协会科技奖三等奖1项，重庆市高等院校优秀教育科研成果三等奖1项，获批国家发明专利44项。担任The Lancet、J Hematol Oncol、Leukemia、Lancet Haematol、Science Bulletin、Chin Med J (Engl)等国际知名期刊编委和审稿专家。在SCI收录期刊发表论文122篇，主编专著3部，副主编2部；执笔行业指南10项，参编29项。目前主要从事造血干细胞移植的临床与基础等方面的研究。E-mail: zhangxxi@sina.comZHANG Xi, E-mail: zhangxxi@sina.com
- 基金信息：
  
  国家自然科学基金国际(地区)合作与交流项目(82020108004);重庆市自然科学基金创新群体科学基金(cstc2021jcyj-cxttX0001);陆军军医大学第二附属医院学科人才建设专项项目(2022XKRC001)
- DOI：10.16016/j.2097-0927.202310109
  中图分类号： R733
- 收稿：2023-10-30，
  
  修回：2023-12-22，
  
  纸质出版：2024-02-28
- 稿件说明：
移动端阅览
张曦. 血液肿瘤精准诊治[J]. 陆军军医大学学报, 2024,46(4):299-310.

Xi ZHANG. Precision diagnosis and treatment for hematological malignancies[J]. Journal of Army Medical University, 2024, 46(4): 299-310.
张曦. 血液肿瘤精准诊治[J]. 陆军军医大学学报, 2024,46(4):299-310. DOI： 10.16016/j.2097-0927.202310109.

Xi ZHANG. Precision diagnosis and treatment for hematological malignancies[J]. Journal of Army Medical University, 2024, 46(4): 299-310. DOI： 10.16016/j.2097-0927.202310109.

摘要

目的

随着对血液肿瘤发病机制的深入研究

血液肿瘤的精准诊断和分层治疗逐年优化提升。近年来在人工智能的推动下

血液肿瘤诊断由人工化、经验化不断向智能化、信息化升级

在未来有望实现高效、高准确率的智能诊断; 同时

小分子药物、抗体类药物、免疫细胞治疗及造血干细胞移植新疗法在不断完善

新药不断涌现

为血液肿瘤的治疗提供了更多选择。本文从血液肿瘤的精准/智能诊断、药物治疗和细胞治疗等3个方面探讨血液肿瘤的精准诊断与治疗。

Abstract

With the in-depth research on the pathogenesis of hematological malignancies

precision diagnosis and stratified treatment have been continuously enhanced and optimized over the years. In recent years

with the aid of artificial intelligence

the diagnosis of the malignancies has been upgraded from manual and empirical to intelligent and mechanized

and it is expected to realize intelligent diagnosis with high efficiency and high accuracy in the future. At the same time

the evolution of small molecule drugs

antibody drugs

immunotherapy and hematopoietic stem cell transplantation

and the emergence of new drugs expand the treatment options for hematological malignancies. In this article

we review the precision diagnosis and treatment of hematological tumors from 3 aspects: precision/intelligent diagnosis

medication

and cellular therapy.

关键词

Keywords

references

张曦, 饶军. 血液肿瘤的精准诊治[J]. 第三军医大学学报, 2020, 42(17): 1675-1680. DOI: 10.16016/j.1000-5404.202008080.

ZHANG X, RAO J. Precision diagnosis and treatment for hematological tumors[J]. J Third Mil Med Univ, 2020, 42 (17): 1675-1680. DOI: 10.16016/j.1000-5404.202008080.

TSAKIROGLOU M, EVANS A, PIRMOHAMED M. Leveraging transcriptomics for precision diagnosis: lessons learnedfrom cancer and sepsis[J]. Front Genet, 2023, 14: 1100352. DOI: 10.3389/fgene.2023.1100352.

DE LEVAL L, ALIZADEH A A, BERGSAGEL P L, et al . Genomic profiling for clinical decision making in lymphoid neoplasms[J ] . Blood, 2022, 140(21): 2193-2227. DOI: 10.1182/blood.2022015854.

DUNCAVAGE E J, BAGG A, HASSERJIAN R P, et al . Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia[J ] . Blood, 2022, 140(21): 2228-2247. DOI: 10.1182/blood.2022015853.

中华医学会血液学分会白血病淋巴瘤学组. 中国成人急性髓系白血病(非急性早幼粒细胞白血病)诊疗指南(2021年版)[J]. 中华血液学杂志, 2021, 42(8): 617-623. DOI: 10.3760/cma.j.issn.0253-2727.2021.08.001.

Leukemia and Lymphoma Group of Chinese Society of Hematology of Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021)[J]. Chin J Hematol, 2021, 42(8): 617-623. DOI: 10.3760/cma.j.issn.0253-2727.2021.08.001.

KHOURY J D, SOLARY E, ABLA O, et al . The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocyt ic/dendritic neoplasms[J ] . Leukemia, 2022, 36(7): 1703-1719. DOI: 10.1038/s41375-022-01613-1.

ARBER D A, ORAZI A, HASSERJIAN R P, et al . International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data[J ] . Blood, 2022, 140(11): 1200-1228. DOI: 10.1182/blood.2022015850.

中华医学会血液学分会白血病淋巴瘤学组. 慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版)[J]. 中华血液学杂志, 2021, 42(1): 5-9. DOI: 10.3760/cma.j.issn.0253-2727.2021.01.002.

Leukemia and Lymphoma Group of Chinese Society of Hematology of Chinese Medical Association. Guideline of the diagnosis and treatment of chronic myelomonocytic leukemia (2021)[J]. Chin J Hematol, 2021, 42(1): 5-9. DOI: 10.3760/cma.j.issn.0253-2727.2021.01.002.

中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中国慢性淋巴细胞白血病工作组. 中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗指南(2022年版)[J]. 中华血液学杂志, 2022, 43(5): 353-358. DOI: 10.3760/cma.j.issn.0253-2727.2022.05.001.

Hematological Oncology Committee of China Anti-Cancer Association, Hematology Committee of Chinese Medical Association, Chinese Working Group for Chronic Lymphocytic Leukemia. The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China(2022)[J]. Chin J Hematol, 2022, 43(5): 353-358. DOI: 10.3760/cma.j.issn.0253-2727.2022.05.001.

ALAGGIO R, AMADOR C, ANAGNOSTOPOULOS I, et al . The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms[J ] . Leukemia, 2022, 36(7): 1720-1748. DOI: 10.1038/s41375-022-01620-2.

FALINI B, MARTELLI M P. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia[J]. Am J Hematol, 2023, 98(3): 481-492. DOI: 10.1002/ajh.26812.

WAGENER R, SEUFERT J, RAIMONDI F, et al . The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma[J ] . Blood, 2019, 133(9): 962-966. DOI: 10.1182/blood-2018-07-864025.

HURWITZ S N, LOCKHART B, ÖNDER Ö, et al . Proteogenomic profiling of high-grade B-cell lymphoma with 11q aberrations and Burkitt lymphoma reveals lymphoid enhancer binding factor 1 as a novel biomarker[J ] . Mod Pathol, 2023, 36(7): 100170. DOI: 10.1016/j.modpat.2023.100170.

GONZALEZ-FARRE B, RAMIS-ZALDIVAR J E, SALMERON-VILLALOBOS J, et al . Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma[J ] . Haematologi ca, 2019, 104(9): 1822-1829. DOI: 10.3324/haematol.2018.207928.

MAURUS K, APPENZELLER S, ROTH S, et al . Panel sequencing shows recurrent genetic FAS alterations in primary cutaneous marginal zone lymphoma[J ] . J Investig Dermatol, 2018, 138(7): 1573-1581. DOI: 10.1016/j.jid.2018.02.015.

MARTIN DE BUSTAMANTE J M, MENDOZA A, LÓPEZ-MUÑOZ S, et al . A new face of fibrin-associated large B-cell lymphoma: Epstein-Barr virus-positive breast implant-associated diffuse large B-cell lymphoma[J ] . J Clin Med, 2023, 12(11): 3614. DOI: 10.3390/jcm12113614.

BAHMAD H F, GOMEZ A S, DEB A, et al . Fluid overload-associated large B-cell lymphoma: a case report and review of literature[J ] . Hematol Rep, 2023, 15(3): 411-420. DOI: 10.3390/hematolrep15030042.

OISHI N, AHMED R, FELDMAN A L. Updates in the classification of T-cell lymphomas and lymphoproliferative disorders[J]. Curr Hematol Malig Rep, 2023: 1-12. DOI: 10.1007/s11899-023-00712-9.

LI Z F, WANG H S, DONG R, et al . Single-cell RNA-seq reveals characteristics of malignant cells and immune microenvironment in subcu taneous panniculitis-like T-cell lymphoma[J ] . Front Oncol, 2021, 11: 611580. DOI: 10.3389/fonc.2021.611580.

OISHI N, BRODY G S, KETTERLING R P, et al . Genetic subtyping of breast implant-associated anaplastic large cell lymphoma[J ] . Blood, 2018, 132(5): 544-547. DOI: 10.1182/blood-2017-12-821868.

MALCOVATI L, STEVENSON K, PAPAEMMANUIL E, et al . SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS[J ] . Blood, 2020, 136(2): 157-170. DOI: 10.1182/blood.2020004850.

JONAK C, ALKON N, RINDLER K, et al . Single-cell RNA sequencing profiling in a patient with discordant primary cutaneous B-cell and T-cell lymphoma reveals micromilieu-driven immune skewing[J ] . Br J Dermatol, 2021, 185(5): 1013-1025. DOI: 10.1111/bjd.20512.

KORNAUTH C, PEMOVSKA T, VLADIMER G I, et al . Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders[J ] . Cancer Discov, 2022, 12(2): 372-387. DOI: 10.1158/2159-8290.CD-21-0538.

RADAKOVICH N, NAGY M, NAZHA A. Machine learning in haematological malignancies[J]. Lancet Haematol, 2020, 7(7): e541-e550. DOI: 10.1016/S2352-3026(20)30121-6.

KIMURA K, TABE Y, AI T, et al . A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA[J ] . Sci Rep, 2019, 9(1): 13385. DOI: 10.1038/s41598-019-49942-z.

WANG W N, LUO M G, GUO P R, et al . Artificial intelligence-assisted diagnosis of hematologic diseases based on bone marrow smears using deep neural networks[J ] . Comput Methods Programs Biomed, 2023, 231: 107343. DOI: 10.1016/j.cmpb.2023.107343.

MATEK C, KRAPPE S, MÜNZENMAYER C, et al . Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set[J ] . Blood, 2021, 138(20): 1917-1927. DOI: 10.1182/blood.2020010568.

MOHLMAN J S, LEVENTHAL S D, HANSEN T, et al . Improving augmented human intelligence to distinguish Burkitt lymphoma from diffuse large B-cell lymphoma cases[J ] . Am J Clin Pathol, 2020, 153(6): 743-759. DOI: 10.1093/ajcp/aqaa001.

XU L N, TETTEH G, LIPKOVA J, et al . Automated whole-body bone lesion detection for multiple myeloma on 68 Ga-pentixafor PET/CT imaging using deep learning methods[J ] . Contrast Media Mol Imaging, 2018, 2018: 2391925. DOI: 10.1155/2018/2391925..

CLICHET V, LEBON D, CHAPUIS N, et al . Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry[J ] . Haematologica, 2023, 108(9): 2435-2443. DOI: 10.3324/haematol.2022.282370.

NGUYEN P C, NGUYEN V, BALDWIN K, et al . Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia[J ] . Br J Haematol, 2023, 202(4): 760-770. DOI: 10.1111/bjh.18802.

ZHU H Y, SHA Y Q, WU W, et al . Zanubrutinib, lenalidomide plus R-CHOP (ZR 2-CHOP) as the first-line treatment for diffused large B-cell lymphoma (DLBCL)[J ] . Blood, 2021, 138(Supplement 1): 3559. DOI: 10.1182/blood-2021-150510.

LEVY A. A study of pirtobrutinib (LOXO-305) versus bendamustine plus rituximab (BR) in untreated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (BRUIN CLL-313)[R/OL ] . (2021-08-27).[2023-01-01 ] . https://clinicaltrials.gov/study/NCT05023980 https://clinicaltrials.gov/study/NCT05023980 .

DREYLING M, SANTORO A, MOLLICA L, et al . Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study[J ] . Am J Hematol, 2020, 95(4): 362-371. DOI: 10.1002/ajh.25711.

MORSCHHAUSER F, TILLY H, CHAIDOS A, et al . Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial[J ] . Lancet Oncol, 2020, 21(11): 1433-1442. DOI: 10.1016/S1470-2045(20)30441-1.

KANG N, ECCLESTON M, CLERMONT P L, et al . EZH2 inhibition: a promising strategy to prevent cancer immune editing[J ] . Epigenomics, 2020, 12(16): 1457-1476. DOI: 10.2217/epi-2020-0186.

YEE A J, HUFF C A, CHARI A, et al . Response to therapy and the effectiveness of treatment with selinexor and dexamethasone in patients with penta-exposed triple-class refractory myeloma who had plasmacytomas[J ] . Blood, 2019, 134(Supplement_1): 3140. DOI: 10.1182/blood-2019-129038.

TERAO T, MATSUOKA K I, UEDA H, et al . Gilteritinib maintenance therapy post-allogenic stem-cell transplantation improves the prognosis of patients with FLT3-mutated AML[J ] . Blood, 2022, 140(Supplement 1): 3290-3291. DOI: 10.1182/blood-2022-163876.

KENNEDY V E, PERETZ C, LEE P, et al . Multi-omic single-cell sequencing reveals genetic and immunophenotypic clonal selection in patients with FLT3-mutated AML treated with gilteritinib/venetoclax[J ] . Blood, 2022, 140(Supplement 1): 2244-2246. DOI: 10.1182/blood-2022-160304.

YAO K, LIU H, YU S, et al . Resistance to mutant IDH inhibitors in acute myeloid leukemia: molecular mechanisms and therapeutic strategies[J ] . Cancer Lett, 2022, 533: 215603. DOI: 10.1016/j.canlet.2022.215603.

MARCUS R, DAVIES A, ANDO K, et al . Obinutuzumab for the first-line treatment of follicular lymphoma[J ] . N Engl J Med, 2017, 377(14): 1331-1344. DOI: 10.1056/NEJMoa1614598.

SEHN L H, CHUA N, MAYER J, et al . Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial[J ] . Lancet Oncol, 2016, 17(8): 1081-1093. DOI: 10.1016/S1470-2045(16)30097-3.

DUELL J, ABRISQUETA P, ANDRE M, et al . Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase Ⅱ L-MIND study[J ] . Haematologica, 2023. [Epub ahead of print ] . DOI: 10.3324/haematol.2023.283480.

MOREAU P, ATTAL M, HULIN C, et al . Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study[J ] . Lancet, 2019, 394(10192): 29-38. DOI: 10.1016/S0140-6736(19)31240-1.

MATEOS M V, SONNEVELD P, HUNGRIA V, et al . Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR [J ] . Clin Lymphoma Myeloma Leuk, 2020, 20(8): 509-518. DOI: 10.1016/j.clml.2019.09.623..

HORWITZ S M, SAVAGE K J, ILLIDGE T, et al . The echelon-2 trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) vs CHOP in frontline treatment of pts with CD30-positive peripheral T-cell lymphoma[J ] . Blood, 2021, 138(Supplement 1): 135. DOI: 10.1182/blood-2021-145124..

SEHN L H, HERTZBERG M, OPAT S, et al . Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): final results of a phase ib/Ⅱ randomized study and single-arm extension (ext) study[J ] . Blood, 2022, 140(Supplement 1): 9464-9467. DOI: 10.1182/blood-2022-157679.

TILLY H, MORSCHHAUSER F, SEHN L H, et al . Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma[J ] . N Engl J Med, 2022, 386(4): 351-363. DOI: 10.1056/nejmoa2115304.

KANTARJIAN H M, DEANGELO D J, STELLJES M, et al . Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia[J ] . N Engl J Med, 2016, 375(8): 740-753. DOI: 10.1056/nejmoa1509277.

SHORT N J, KANTARJIAN H, ALVARADO Y, et al . A phase Ⅱ study of inotuzumab ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia[J ] . Blood, 2021, 138(Supplement 1): 2299. DOI: 10.1182/blood-2021-154124.

CHEVALLIER P, LEGUAY T, DOUBEK M, et al . Fractionated inotuzumab ozogamicin combined with low-i ntensity chemotherapy provides very good outcome in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: first results from the EWALL-INO study[J ] . Blood, 2021, 138(Supplement 1): 511. DOI: 10.1182/blood-2021-148625.

OLSZEWSKI A J, AVIGDOR A, BABU S, et al . Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma[J ] . Blood, 2022, 140(Supplement 1): 1778-1780. DOI: 10.1182/blood-2022-157768.

TOPP M S, TANI M, DICKINSON M, et al . Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase ib study[J ] . Blood, 2022, 140(Supplement 1): 1775-1777. DOI: 10.1182/blood-2022-157732.

JABBOUR E J, SHORT N J, JAIN N, et al . Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 -4 and higher[J ] . Am J Hematol, 2022, 97(9): 1135-1141. DOI: 10.1002/ajh.26634..

YAO L, YIN H, HONG M, et al . RNA methylation in he matological malignancies and its interactions with other epigenetic modifications[J ] . Leukemia, 2021, 35(5): 1243-1257. DOI: 10.1038/s41375-021-01225-1.

SEKERES M A, OTHUS M, LIST A F, et al . Randomized phase Ⅱ study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117[J ] . J Clin Oncol, 2017, 35(24): 2745-2753. DOI: 10.1200/JCO.2015.66.2510.

WEI A H, DÖHNER H, POCOCK C, et al . Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission[J ] . N Engl J Med, 2020, 383(26): 2526-2537. DOI: 10.1056/nejmoa2004444.

MONTESINOS P, RECHER C, VIVES S, et al . Ivosidenib and azacitidine in IDH 1-mutated acute myeloid leukemia[J ] . N Engl J Med, 2022, 386(16): 1519-1531. DOI: 10.1056/NEJMoa2117344..

DINARDO C D, SCHUH A C, STEIN E M, et al . Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial[J ] . Lancet Oncol, 2021, 22(11): 1597-1608. DOI: 10.1016/S1470-2045(21)00494-0.

WANG L, LUO J, CHEN G, et al . Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study[J ] . Clin Epigenet, 2020, 12(1): 132. DOI: 10.1186/s13148-020-00923-4.

DAVER N, GARCIA-MANERO G, BASU S, et al . Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase Ⅱ study[J ] . Cancer Discov, 2019, 9(3): 370-383. DOI: 10.1158/2159-8290.CD-18-0774.

BURKE M J, KOSTADINOV R, SPOSTO R, et al . Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study[J ] . Clin Cancer Res, 2020, 26(10): 2297-2307. DOI: 10.1158/1078-0432.CCR-19-1251.

SHI Y K, JIA B, XU W, et al . Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China[J ] . J Hematol Oncol, 2017, 10(1): 69. DOI: 10.1186/s13045-017-0439-6.

刘红云, 董松, 曾韫璟, 等. 西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察[J]. 第三军医大学学报, 2020, 42(17): 1724-1729. DOI: 10.16016/j.1000-5404.202006020.

LIU H Y, DONG S, ZENG Y J, et al . Maintenance therapy with chidamide prevents from postoperative recurrence after autologous hematopoietic stem cell transplantation for peripheral T cell lymphoma[J ] . J Third Mil Med Univ, 2020, 42(17): 1724-1729. DOI: 10.16016/j.1000-5404.202006020.

XIA L, GUO H P, WU X, et al . Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia[J ] . Theranostics, 2023, 13(4): 1289-1301. DOI: 10.7150/thno.80054.

WEI J S, GUO Y L, WANG Y, et al . Clinical development of CAR T cell therapy in China: 2020 update[J ] . Cell Mol Immunol, 2021, 18(4): 792-804. DOI: 10.1038/s41423-020-00555-x.

ZHANG C, HE J P, LIU L, et al . Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia[J ] . Blood Cancer J, 2022, 12(6): 1-9. DOI: 10.1038/s41408-022-00688-4.

CHEN Y H, CHENG Y F, SUO P, et al . Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cel l transplantation[J ] . Br J Haematol, 2017, 179(4): 598-605. DOI: 10.1111/bjh.14923.

ZHANG C, WANG X Q, ZHANG R L, et al . Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant[J ] . Leukemia, 2021, 35(6): 1563-1570. DOI: 10.1038/s41375-020-01056-6.

WANG Y Q, HUANG R H, WANG Z, et al . Facing challenges with hope: universal immune cells for hematologic malignancies[J ] . Cancer Biol Med, 2023, 20(4): 229-247. DOI: 10.20892/j.issn.2095-3941.2022.0759.

LI S Q, WANG X X, LIU L, et al . CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies[J ] . Leukemia, 2023, 37(11): 2176-2186. DOI: 10.1038/s41375-023-02018-4..

HUANG R H, WEN Q, ZHANG X. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022[J]. J Hematol Oncol, 2023, 16(1): 35. DOI: 10.1186/s13045-023-01435-3.

HUANG R H, WANG X Q, ZHANG X.Unity brings strength: combination of CAR-T cell therapy and HSCT[J]. Cancer Lett, 2022, 549: 215721. DOI: 10.1016/j.canlet.2022.215721.

LIU Y, AN L N, HUANG R H, et al . Strategies to enhance CAR-T persistence[J ] . Biomark Res, 2022, 10(1): 1-18. DOI: 10.1186/s40364-022-00434-9.

WANG X Q, HUANG R H, ZHANG X H, et al . Current status and prospects of hematopoietic stem cell transplantation in China[J ] . Chin Med J, 2022, 135(12): 1394-1403. DOI: 10.1097/cm9.0000000000002235.

GAO L, ZHANG Y Q, WANG S B, et al . Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial[J ] . J Clin Oncol, 2020, 38(36): 4249-4259. DOI: 10.1200/JCO.19.03277.

XUAN L, DAI M, JIANG E L, et al . The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial[J ] . Lancet Haematol, 2023, 10(3): e178-e190. DOI: 10.1016/S2352-3026(22)00375-1.

GAO L, ZHANG Y Q, HU B Y, et al . Phase Ⅱ multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation[J ] . J Clin Oncol, 2016, 34(24): 2843-2850. DOI: 10.1200/JCO.2015.65.3642.

王景枝, 刘开彦, 许兰平, 等. 嵌合型CD25单抗治疗造血干细胞移植术后急性移植物抗宿主病[J]. 中华内科杂志, 2008, 47(11): 923-925. DOI: 10.3321/j.issn:0578-1426.2008.11.014.

WANG J Z, LIU K Y, XU L P, et al . Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J ] . Chin J Intern Med, 2008, 47(11): 923-925. DOI: 10.3321/j.issn:0578-1426.2008.11.014.

ZHAO K, LIN R, FAN Z P, et al . Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial[J ] . J Hematol Oncol, 2022, 15(1): 22. DOI: 10.1186/s13045-022-01240-4.

中华医学会血液学分会造血干细胞应用学组, 中国抗癌协会血液病转化委员会. 慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(4): 265-275. DOI: 10.3760/cma.j.issn.0253-2727.2021.04.001.

Hematopoietic Stem Cell Application Group of Chinese Society of Hematology of Chinese Medical Association, China Association for the Prevention of Hematology Diseases. Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)[J]. Chin J Hematol, 2021, 42(4): 265-275. DOI: 10.3760/cma.j.issn.0253-2727.2021.04.001.

FAN S, HUO W X, YANG Y, et al . Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis[J ] . Front Immunol, 2022, 13: 954268. DOI: 10.3389/fimmu.2022.954268.

WU H W, SHI J M, LUO Y, et al . Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation[J ] . JAMA Netw Open, 2021, 4(1): e2034750. DOI: 10.1001/jamanetworkopen.2020.34750.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肝细胞癌临床诊治新进展：综合治疗策略的演变

免疫治疗联合靶向治疗及化疗在微卫星稳定型转移性结直肠癌患者三线治疗中的疗效和安全性

新药时代下如何为异基因造血干细胞移植赋能

维生素E脂质体纳米颗粒转运siRNA抑制丙型肝炎病毒核心蛋白表达的实验研究